AKRO Akero Therapeutics Inc
Price (delayed)
$51.84
Market cap
$3.62B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.78
Enterprise value
$3.34B
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein,
Highlights
AKRO's equity is up by 27% year-on-year but it is down by 7% since the previous quarter
AKRO's net income has shrunk by 98% YoY and by 16% QoQ
Akero Therapeutics's EPS has shrunk by 66% YoY and by 10% QoQ
Key stats
What are the main financial stats of AKRO
Market
Valuations
Earnings
Shares outstanding
69.8M
Market cap
$3.62B
Enterprise value
$3.34B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$269.27M
Net income
-$237.22M
EBIT
-$232.86M
EBITDA
-$232.6M
Free cash flow
-$211.64M
Per share
Balance sheet
Liquidity
EPS
-$3.78
EPS diluted
-$3.78
Free cash flow per share
-$3.05
Book value per share
$10.63
Revenue per share
$0
TBVPS
$11.77
Total assets
$817.55M
Total liabilities
$79.22M
Debt
$35.73M
Equity
$738.33M
Working capital
$703.6M
Debt to equity
0.05
Current ratio
17.25
Quick ratio
16.57
Net debt/EBITDA
1.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.9%
Return on equity
-32.5%
Return on invested capital
-54.8%
Return on capital employed
-30.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKRO stock price
How has the Akero Therapeutics stock price performed over time
Intraday
2.49%
1 week
2.61%
1 month
102.5%
1 year
115.64%
YTD
86.34%
QTD
86.34%
Financial performance
How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$269.27M
Net income
-$237.22M
Gross margin
N/A
Net margin
N/A
AKRO's net income has shrunk by 98% YoY and by 16% QoQ
Akero Therapeutics's operating income has plunged by 97% YoY and by 15% from the previous quarter
Growth
What is Akero Therapeutics's growth rate over time
Valuation
What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
4.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has shrunk by 66% YoY and by 10% QoQ
The stock's P/B is 121% above its last 4 quarters average of 2.2 and 22% above its 5-year quarterly average of 4.0
AKRO's equity is up by 27% year-on-year but it is down by 7% since the previous quarter
Efficiency
How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on equity has decreased by 25% YoY and by 10% QoQ
The ROA has contracted by 25% YoY and by 10% from the previous quarter
Akero Therapeutics's return on invested capital has increased by 8% YoY but it has decreased by 7% QoQ
Dividends
What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKRO.
Financial health
How did Akero Therapeutics financials performed over time
The total liabilities has soared by 52% year-on-year and by 18% since the previous quarter
Akero Therapeutics's quick ratio has decreased by 32% QoQ and by 15% YoY
AKRO's debt is 95% smaller than its equity
AKRO's debt is up by 39% year-on-year
AKRO's equity is up by 27% year-on-year but it is down by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.